ESTABLISHING NEW STRATEGIES IN AF DETECTION

Make the LINQ between atrial fibrillation and stroke for patients at high risk.

Reveal LINQ™ Insertable Cardiac Monitoring System

Medtronic
AF + STROKE
A GLOBAL HEALTH CHALLENGE

15 MILLION PEOPLE WORLDWIDE EXPERIENCE A STROKE EACH YEAR¹

1 IN 4 OF ALL STROKES ARE CAUSED BY AF²

AF DETECTION AND TREATMENT MATTERS

5-FOLD
increase in ischemic stroke risk for AF patients.³

2X
more likely for AF-related ischemic stroke to be fatal as non-AF stroke.⁴

67%
decrease in AF patient stroke risk with oral anticoagulants.⁴

DIFFICULTIES IN AF DETECTION

Symptoms are not a reliable indicator of AF.⁵

~90%
of AF episodes may be asymptomatic.⁵

1/5th
of patient symptoms thought to be AF were actually due to AF.⁶

STROKE
is the first symptom for ~20% of patients who have an AF-related stroke.³

1 IN 4 OF ALL STROKES ARE CAUSED BY AF²

Short-term and intermittent cardiac monitoring may miss many patients with paroxysmal AF⁶-⁸

- Short-term monitoring via 24-hour Holter has low sensitivity and negative predictive value for AF detection.⁶
- Intermittent and symptom-based monitoring has a significantly lower sensitivity and negative predictive value for AF detection compared with continuous monitoring.⁷

Longer, continuous monitoring periods result in higher AF detection.⁸
Prospective, global, multicenter study
- 446 patients enrolled, 385 patients received a Reveal™ ICM and were included in the analysis cohort
- Patients were followed for an average of 22.5 months + 7.7 months

A CHADS\textsubscript{2} score of ≥ 3 or CHADS\textsubscript{2} = 2 and at least 1 of the following:
- Coronary artery disease
- Renal impairment (GFR 30–60 ml/min)
- Sleep apnea
- Chronic obstructive pulmonary disease
No AF found after 24 hours of cardiac monitoring.

Primary
Determine the incidence rate of AF lasting ≥ 6 minutes in patients who are at high risk of having AF and stroke.

Secondary
- Identify predictors of AF onset
- Characterize the timing and nature of clinical actions relative to detection of AF

The Reveal AF study may have important implications for prophylactic AF screening and treatment in high-risk patients.\textsuperscript{9}

Visit medtronic.com/RevealAF for complete study information.
INFORM YOUR CLINICAL DECISIONS

New strategies for patients at high risk for AF and stroke

AF incidence by CHADS\textsubscript{2} subgroup\textsuperscript{9}

<table>
<thead>
<tr>
<th>CHADS 4</th>
<th>CHADS 3</th>
<th>CHADS 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>81</td>
<td>36</td>
<td>11</td>
</tr>
<tr>
<td>83</td>
<td>39</td>
<td>11</td>
</tr>
<tr>
<td>117</td>
<td>102</td>
<td>89</td>
</tr>
</tbody>
</table>

Number of Subjects at Risk: 104, 119, 112

There was no significant difference in detection rates between patients with CHADS\textsubscript{2} 2, 3, and 4 or more.\textsuperscript{5}

REVEAL AF STUDY SECONDARY END POINTS

AF detected through Reveal ICM was found to be actionable by physicians.\textsuperscript{9}

56.3% of patients were prescribed oral anticoagulants during follow-up.\textsuperscript{9}

14.8% of patients were prescribed rhythm-control medication during follow-up.\textsuperscript{9}

DETECT AF IN HIGH-RISK PATIENTS WITH THE REVEAL LINQ\textsuperscript{TM} ICM SYSTEM

99.7%

Highest published AF detection accuracy on the market at 99.7% streamlines data review\textsuperscript{10}

AN ADVANCED MONITORING SOLUTION

Reveal LINQ ICM

MyCareLink\textsuperscript{TM} Patient Monitor

CareLink\textsuperscript{TM} Network and Reports

0 episodes @ 1 min

4 episodes @ 7.5 minutes each

6.5 min prior

1 min

Patient-activated

3 episodes @ 10 minutes each

9 min prior

1 min

Patient-activated

2 episodes @ 15 minutes each

14 min prior

1 min

Patient-activated

1 min

Patient-activated

Patient Assistant
One-button symptom marking with the ability to store multiple patient-activated episodes.
UNMATCHED ACCURACY

DRIVING ACCURACY EVOLUTION

Dedicated to advancing accuracy with every device generation.

INDUSTRY-LEADING TRURHYTHM DETECTION

Our newest detection algorithms streamline episode review without sacrificing sensitivity.

SELF-LEARNING
NEW AF algorithm learns and adapts to patients with sinus arrhythmia.

NEW self-learning threshold rejects false AF in patients with history of P waves.

SUPERIOR ACCURACY IN AF DETECTION

Demonstrating superior atrial fibrillation detection accuracy through our performance results.

Advanced AF detection*

<table>
<thead>
<tr>
<th></th>
<th>AF BURDEN</th>
<th>AF EPISODE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reveal LINQ ICM</td>
<td>Sensitivity 98.9%</td>
<td>Sensitivity 99.7%</td>
</tr>
<tr>
<td>Confirm ICM</td>
<td>PPV 99.0%</td>
<td>PPV 95.3%</td>
</tr>
<tr>
<td></td>
<td>PPV 97.3%</td>
<td>PPV 59.1%</td>
</tr>
</tbody>
</table>

*In known AF patients.

STREAMLINED EPISODE REVIEW

8X more false positives shown by other ICM.10,11

AF False Positive %

- Confirm-AF: 39.3%
- BioMonitor 2-AF: 26.3%
- Reveal LINQ: 9.6%
- Reveal LINQ with TruRhythm Detection: 4.7%

*% of False Positives = (1 –Episode PPV). Episode PPV may vary (gross, patient average).
AF is often paroxysmal and difficult to detect with traditional monitoring modalities.5-8

~90% of AF episodes may be asymptomatic.5

STROKE is the first symptom for ~20% of patients who have an AF-related stroke.3

REVEAL AF STUDY

Demonstrating the need for long-term, continuous cardiac monitoring for patients at high risk for AF and stroke.9

medtronic.com/RevealAF

40% AF detection rate at 30 months.9  123 days was the median time to AF detection in high-risk patients.9  84.5% of patients with AF would have been missed if only monitored for 30 days.9